123 related articles for article (PubMed ID: 18985036)
1. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
[TBL] [Abstract][Full Text] [Related]
2. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B
Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418
[TBL] [Abstract][Full Text] [Related]
3. Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.
Portella G; Borselli C; Santoro M; Gerbasio D; D'Armiento MR; Dumont JE; Ledent C; Rothstein JL; Vecchio G; Fusco A
Oncol Res; 2001; 12(8):347-54. PubMed ID: 11589306
[TBL] [Abstract][Full Text] [Related]
4. Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland.
Prost G; Bernier-Valentin F; Croset M; Rousset B
Endocr Relat Cancer; 2009 Sep; 16(3):873-84. PubMed ID: 19509066
[TBL] [Abstract][Full Text] [Related]
5. Histopathological changes induced by selective inactivation of menin on the thyroid gland in RET÷PTC3 and E7 transgenic mice. A study of 77 cases.
Căpraru OM; Berger N; Gadot N; Decaussin-Petrucci M; Zhang C; Borda A; Szilágyi T; Borson-Chazot F; Selmi-Ruby S
Rom J Morphol Embryol; 2016; 57(1):91-8. PubMed ID: 27151693
[TBL] [Abstract][Full Text] [Related]
6. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
[TBL] [Abstract][Full Text] [Related]
7. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
8. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
Fiore AP; Fuziwara CS; Kimura ET
Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.
Shinohara S; Rothstein JL
Oncogene; 2004 Sep; 23(45):7571-9. PubMed ID: 15326486
[TBL] [Abstract][Full Text] [Related]
10. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.
Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L
PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995
[TBL] [Abstract][Full Text] [Related]
11. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
Zhou D; Li Z; Bai X
Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
[TBL] [Abstract][Full Text] [Related]
12. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
[TBL] [Abstract][Full Text] [Related]
13. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
14. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.
Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA
Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106
[TBL] [Abstract][Full Text] [Related]
15. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
16. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of RET/PTC mutations in papillary thyroid cancers in Turkish population and its relation between tumor histopathology and prognostic factors.
Erdoğan M; Berdeli A; Karadeniz M; Ertan Y; Cetinkalp S; Saygili F; Tuncyurek M; Yilmaz C; Tuzun M; Kabalak T; Uluer H; Ozgen AG
Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):225-30. PubMed ID: 18393128
[TBL] [Abstract][Full Text] [Related]
18. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
20. Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours.
Coppée F; Depoortere F; Bartek J; Ledent C; Parmentier M; Dumont JE
Oncogene; 1998 Aug; 17(5):631-41. PubMed ID: 9704929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
